Evidence map›Paper›PMID 37190903›Full record

ArticleInternational journal of cancer2023

Cancer incidence and mortality in 23 000 patients with type 1 diabetes in the UK: Long-term follow-up.

Anthony J Swerdlow, Michael E Jones, Stefan D Slater, Andrew C F Burden, Johannes L Botha, Norman R Waugh, Andrew D Morris, Wendy Gatling, Kathleen M Gillespie, Christopher C Patterson and 1 more

Open access · hybridAbstract read
In one paragraph

Article in International journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 2 countries.

Anthony J SwerdlowDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.ORCID 0000-0001-5550-4159
Michael E JonesDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Stefan D Slater80 Whitehouse Rd, Edinburgh, UK.
Andrew C F BurdenTop Orchard, Broadhembury, Honiton, Devon, UK.
Johannes L BothaMeanwood, Leeds, UK.
Norman R WaughDivision of Health Sciences, University of Warwick, Coventry, UK.
Andrew D MorrisHealth Data Research UK, London, UK.
Wendy GatlingDepartment of Diabetes, Poole Hospital NHS Trust, Dorset, UK.
Kathleen M GillespieDiabetes and Metabolism, Bristol Medical School, University of Bristol, Bristol, UK.
Christopher C PattersonDepartment of Epidemiology and Public Health, Queen's University, Belfast, UK.
Minouk J SchoemakerGlobal Database Studies, Real World Solutions at IQVIA, Netherlands.
Institute of Cancer Research · GBAt Bristol · GBHealth Data Research UK · GBHoniton Hospital · GBIQVIA (United Kingdom) · GBLeeds College of Building · GBPoole Hospital · GBQueen's University Belfast · GBThe White House · USUniversity of Warwick · GB

Funding

Medical Research Council
6 · The paper itself

Abstract

Type 2 diabetes is associated with raised risk of several cancers, but for type 1 diabetes risk data are fewer and inconsistent We assembled a cohort of 23 473 UK patients with insulin-treated diabetes diagnosed at ages <30, almost all of whom will have had type 1 diabetes, and for comparison 5058 diagnosed at ages 30 to 49, of whom we estimate two-thirds will have had type 2, and followed them for an average of 30 years for cancer incidence and mortality compared with general population rates. Patients aged <30 at diabetes diagnosis had significantly raised risks only for ovarian (standardised incidence ratio = 1.58; 95% confidence interval 1.16-2.11; P < .01) and vulval (3.55; 1.94-5.96; P < .001) cancers, with greatest risk when diabetes was diagnosed at ages 10-14. Risks of cancer overall (0.89; 0.84-0.95; P < .001) and sites including lung and larynx were significantly diminished. Patients diagnosed with diabetes at ages 30 to 49 had significantly raised risks of liver (1.76;1.08-2.72) and kidney (1.46;1.03-2.00) cancers, and reduced risk of cancer overall (0.89; 0.84-0.95). The raised ovarian and vulval cancer risks in patients with type 1 diabetes, especially with diabetes diagnosed around pubertal ages, suggest possible susceptibility of these organs at puberty to metabolic disruption at diabetes onset. Reduced risk of cancer overall, particularly smoking and alcohol-related sites, might reflect adoption of a healthy lifestyle.

Indexed as

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2NeoplasmsFollow-Up StudiesHumansIncidenceRisk FactorsUnited Kingdomcancercohorttype 1 diabetes

Identifiers

PMID37190903
PMCPMC10952206
OpenAlexW4376641137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.